The Enterprise Value as of September 2024 (TTM) for Inhibrx, Inc. (INBX) is 32.11M

According to Inhibrx, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 32.11M. This represents a change of -97.18% compared to the average of 1.14B of the last 4 quarters.

Inhibrx, Inc. (INBX) Historical Enterprise Value (quarterly & annually)

How has INBX Enterprise Value performed in the past?

The mean historical Enterprise Value of Inhibrx, Inc. over the last ten years is 959.84M. The current 32.11M Enterprise Value has changed 234.57% with respect to the historical average. Over the past ten years (40 quarters), INBX's Enterprise Value was at its highest in in the December 2023 quarter at 1.99B. The Enterprise Value was at its lowest in in the June 2024 quarter at -25790079.04.

Inhibrx, Inc. (INBX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Inhibrx, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibrx, Inc. (INBX) Average Enterprise Value

How has INBX Enterprise Value performed in the past?

The current Enterprise Value of Inhibrx, Inc. (INBX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Inhibrx, Inc. (INBX) Enterprise Value vs. Peers

How is INBX’s Enterprise Value compared to its peers?

Inhibrx, Inc.’s Enterprise Value is less than Crinetics Pharmaceuticals, Inc. (4.07B), less than Merus N.V. (2.80B), less than Lyell Immunopharma, Inc. (232.72M), greater than Kronos Bio, Inc. (12.94M), less than Opthea Limited (526.23M), less than Mineralys Therapeutics, Inc. (507.98M), less than Eliem Therapeutics, Inc. (327.52M), less than Anebulo Pharmaceuticals, Inc. (49.05M), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Celcuity Inc. (627.80M), less than Enliven Therapeutics, Inc. (961.83M), less than Monte Rosa Therapeutics, Inc. (295.46M), less than Design Therapeutics, Inc. (274.08M), greater than Werewolf Therapeutics, Inc. (-5104292.00), less than Ikena Oncology, Inc. (47.83M), less than Stoke Therapeutics, Inc. (581.99M), less than Protagonist Therapeutics, Inc. (2.38B), less than DICE Therapeutics, Inc. (2.21B), less than Larimar Therapeutics, Inc. (400.79M), less than Viridian Therapeutics, Inc. (1.29B),

Build a custom stock screener for Inhibrx, Inc. (INBX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibrx, Inc. (INBX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibrx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.